Vertex Pharmaceuticals Total Liabilities decreased by 7.5% to $6.98B in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 13.9%, from $6.12B to $6.98B. Over 5 years (FY 2020 to FY 2025), Total Liabilities shows an upward trend with a 17.9% CAGR.
A high level of total liabilities relative to equity indicates a more leveraged capital structure and higher financial risk.
The aggregate of all current and non-current debts and obligations owed by the company to external parties. It represent...
Analyzed alongside Total Assets to determine the Debt-to-Asset ratio, which is a standard measure of solvency across all industries.
total_liabilities| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $3.03B | $3.09B | $3.33B | $3.35B | $3.65B | $3.68B | $4.24B | $4.54B | $4.88B | $5.21B | $5.15B | $5.37B | $5.36B | $6.61B | $6.12B | $6.38B | $6.86B | $7.54B | $6.98B |
| QoQ Change | — | +2.1% | +7.9% | +0.5% | +8.9% | +0.8% | +15.3% | +7.2% | +7.4% | +6.9% | -1.2% | +4.3% | -0.2% | +23.4% | -7.3% | +4.3% | +7.5% | +9.9% | -7.5% |
| YoY Change | — | — | — | — | +20.6% | +19.1% | +27.2% | +35.6% | +33.7% | +41.8% | +21.5% | +18.3% | +9.8% | +26.8% | +18.9% | +18.9% | +28.1% | +14.1% | +13.9% |
We use cookies for analytics. See our Privacy and Cookie Policy.